Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. (Q45987534)
Jump to navigation
Jump to search
scientific article published in March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. |
scientific article published in March 2014 |
Statements
1 reference
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. (English)
1 reference
Pasi A Jänne
1 reference
Roger B Cohen
1 reference
A Douglas Laird
1 reference
Sandrine Macé
1 reference
Jeffrey A Engelman
1 reference
Rodrigo Ruiz-Soto
1 reference
Kevin Rockich
1 reference
Jianbo Xu
1 reference
Geoffrey I Shapiro
1 reference
Pablo Martinez
1 reference
1 March 2014
1 reference
9
1 reference
3
1 reference
316-323
1 reference